Stromal Tumor-Infiltrating Lymphocytes Are Prognostic of Survival in Breast Cancer

The presence of stromal tumor-infiltrating lymphocytes is associated with recurrence-free survival in HER2-positive breast cancer.
The presence of stromal tumor-infiltrating lymphocytes is associated with recurrence-free survival in HER2-positive breast cancer.

The presence of stromal tumor-infiltrating lymphocytes (STILs) is associated with recurrence-free survival (RFS) in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with chemotherapy alone; however, this association was not seen in women treated with chemotherapy plus trastuzumab. These study findings were published online first in JAMA Oncology.

The presence of tumor-infiltrating lymphocytes is a prognostic factor in patients with triple-negative breast cancer. 

In this study, the researchers sought to determine the association between presence of STILs and RFS in women with early stage HER2-positive breast cancer who received chemotherapy alone or chemotherapy plus trastuzumab. The women included in this study were clinical trial participants assigned to 2 of the 3 arms of the N9831 trial.

Using Cox models, the researchers assessed hematoxylin eosin-stained tumor slides from N9831 trial participants who received doxorubicin-cyclophosphamide followed by weekly paclitaxel (489 patients in arm A [standard chemotherapy]) or doxorubicin-cyclophosphamide followed by weekly paclitaxel plus trastuzumab followed by trastuzumab alone (456 patients in arm C [chemotherapy plus trastuzumab]). Assessment for STILs was done at an academic medical center. Mean follow-up was 4.4 years.

The 10-year Kaplan-Meier estimates for RFS in the patients from arm A were 90.9% for those with high levels of STILs and 64.5% for those with low levels of STILs. RFS estimates for the patients from arm C were 80.0% for those with high levels of STILs and 80.1% for those with low levels of STILs.

Interaction between trastuzumab treatment and STIL status was statistically significant, and remained significantly associated with RFS in arm A but not in arm C on multivariable analysis.

Furthermore, these results are in contrast to previous reports of an association between high levels of STILs and increased benefit of trastuzumab treatment in patients with HER2-positive breast cancer.

REFERENCE

1. Perez EA, Ballman KV, Tenner KS, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer [published online ahead of print October 15, 2015]. AMA Oncol. doi:10.1001/jamaoncol.2015.3239.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs